Publications by authors named "Donald Sarubbi"
Article Synopsis
- The study aimed to assess the safety and pharmacokinetics of a new drug, BI 1291583, which inhibits cathepsin C to potentially reduce inflammation in bronchiectasis patients.
- Conducted as a randomized, double-blind, placebo-controlled trial, it involved healthy Japanese males and evaluated both single and multiple doses for any related adverse events and drug absorption levels.
- Results indicated that the drug was safe and well-tolerated, with no serious side effects and an adequate benefit-risk ratio, suggesting it can be used in future clinical trials involving bronchiectasis patients without needing dose adjustments.
Background: Obesity is a complex disease associated with multiple concurrent complications, and the coordinated targeting of multiple pathways in pharmacological treatment may improve weight loss outcomes. During synthesis, ghrelin is converted from the 'inactive' unacylated ghrelin (UAG) to the active acylated ghrelin (AG) by the enzyme ghrelin-O-acyltransferase (GOAT), stimulating appetite and food intake.
Aims: To report the results of two Phase I studies investigating single rising doses (SRDs) or multiple rising doses (MRDs) of the novel oral GOAT inhibitor BI 1356225 versus placebo in male and postmenopausal/sterilised female subjects with overweight or obesity.